Albert Bourla

Albert Bourla is a Greek-born pharmaceutical executive who has served as Chairman and Chief Executive Officer of Pfizer Inc. since January 2019. A Doctor of Veterinary Medicine with a Ph.D. in the Biotechnology of Reproduction from Aristotle University of Thessaloniki, Bourla joined Pfizer in 1993 in its animal health division in Greece and advanced through successive leadership roles in Europe and the United States, including as Chief Operating Officer from 2018.

Under Bourla's leadership, Pfizer collaborated with BioNTech to develop BNT162b2, the first mRNA-based COVID-19 vaccine authorized for emergency use by the U.S. FDA in December 2020 after a clinical trial demonstrating over 90% efficacy against symptomatic disease in initial strains. The vaccine's accelerated timeline—from candidate selection to authorization in under a year—leveraged parallel processes, prior mRNA research, and substantial investment, enabling billions of doses to be distributed globally and credited by some analyses with averting millions of deaths. However, subsequent data revealed waning efficacy against infection and transmission from variants like Omicron, contradicting earlier assertions by Bourla that the vaccine would largely prevent spread.

Bourla's tenure has included significant company achievements, such as improved R&D productivity, but also controversies, including whistleblower reports of data falsification at a trial site, regulatory findings of misleading efficacy claims for pediatric boosters, and a 2023 lawsuit by Texas alleging Pfizer misrepresented vaccine durability and suppressed adverse event discussions. For his role in vaccine development, he received the 2022 Genesis Prize and the 2024 AACR Outstanding Achievement Award.